The primary objective of this study is to measure camouflaging behaviors (i.e., behaviors that hide autistic symptoms) and social compensation (i.e., behaviors that explicitly support social interaction) in individuals with and without ASD using an online self-report questionnaire - the CAT-Q.

This study aims to collect data from patients seen at CHOP, CHOP's 3550 Market St. primary care location, Penn, or from the surrounding communities. If you choose to participate, we will take an optional blood, saliva, and/or stool sample, have you complete computer testing that measures things like your reaction time and your memory, have you complete questionnaires, and we will interview you and your parent or legal guardian to ask questions about your life experiences and perceptions, and past and current mental health.

The purpose of this study is to test an investigational medication in children and adolescents aged 5-17 years old with irritability associated with autism spectrum disorder (ASD). The name of the medication being tested in this study is pimavanserin. This medication is investigational because it has not been approved by the FDA for the treatment of irritability associated with autism. The main risks of this study are from the medication, which include nausea, dizziness, and sleepiness.